Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
16 September 2008 - 10:00PM
PR Newswire (US)
ORMD 0901 is Being Developed as an Oral Dosage Form of a
GLP1-analog Aimed at Improving Glycemic Control in Adults With Type
2 Diabetes JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/
-- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of
oral drug delivery systems, announced today that it has launched
pre-clinical trials of ORMD 0901, a GLP1-analog. ORMD 0901 belongs
to the Incretin family of drugs which helps to manage diabetes,
including reduction in blood glucose levels and inhibiting glucagon
secretion. Incretins have been cited in causing regeneration of
pancreatic insulin secreting cells, and in tissue protective
properties including protection of the heart. GLP1 and analogs are
associated with gradual weight loss, which is very desirable in
diabetes patients. "The launch of pre-clinical trials of ORMD 0901
and expansion of Oramed's platform marks the next strategic
milestone for our company as we demonstrate the effectiveness of
our oral delivery technology in yet another important family of
polypeptide drugs for diabetes, that are until now only available
in injection form," said Oramed CEO Nadav Kidron. We plan to
conduct the ORMD 0901 trials at Hadassah University Medical Center
and they are expected to conclude by the end of 2008. Oramed plans
to launch phase 2b trials of ORMD 0801, its oral insulin capsule,
in India in the first quarter of 2009. About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes
through its patented flagship product, an orally ingestible insulin
capsule currently in phase 2 clinical trials. Established in 2006,
Oramed's technology is based on over 25 years of research by top
research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
Jerusalem. For more information, please visit
http://www.oramed.com/ Forward-looking statements Some of the
statements contained in this press release are forward-looking
statements which involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results,
performance or achievements of the company to differ materially
from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any
forward-looking statements. Company and Investor Relation Contacts:
Oramed Pharmaceuticals Eric Rosenberg Cell: +972-54-566-7713
Office: +972-2-566-0001 Email: Media Contacts: Ruder Finn Israel
for Oramed Matthew Krieger Cell: +972-54-467-6950 Office:
+972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceuticals Inc.
CONTACT: Company and Investor Relation Contacts: Oramed
Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office:
+972-2-566-0001, Email: ; Media Contacts: Ruder Finn Israel for
Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office:
+972-2-589-2003, Email:
Copyright